JPRN-UMIN000047127
Not yet recruiting
未知
Phase II study to evaluate the safety and efficacy of endoscopic radiofrequency ablation of the bile duct using the Habib Endo HPB catheter in patients with unresectable cholangiocarcinoma after biliary stent placement. - Phase II study to evaluate the safety and efficacy of endoscopic radiofrequency ablation of the bile duct using the Habib Endo HPB catheter in patients with unresectable cholangiocarcinoma after biliary stent placement.
ConditionsCholangiocarcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Cholangiocarcinoma
- Sponsor
- Yokohama City University
- Enrollment
- 10
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Patients in poor general condition who cannot undergo endoscopy (2\) Patients taking more than 2 antiplatelet/anticoagulant drugs (3\) Patients with a pacemaker implanted (4\) Patients with a fever of 37\.5 or higher and suspected cholangitis (5\) Other patients deemed unsuitable for the procedure by the physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Phase II study of multimodality treatment for ATRTAtypical teratoid rhabdoid tumorD016543JPRN-jRCTs051200071Junichi Hara50
Recruiting
Phase 2
Phase II study of new risk classification and high-dose chemotherapy for medulloblastomaJPRN-jRCTs051200021Hara Junichi229
Not yet recruiting
Phase 2
Phase II study to evaluate the efficacy and safety of mirogabalin for CIPN in patients with gastrointestinal cancer.esophageal cancer, gastric cancer, small bowel cancer, colon cancer, pancreatic cancerJPRN-UMIN000049555ational Cancer Center Hospital30
Recruiting
Phase 2
Evaluation of the efficacy of bioadhesive barrier-forming oral liquid gel (Episil) for prevention of oral mucositisJPRN-jRCTs062220023Takano HIdeyuki50
Recruiting
Phase 2
Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapyJPRN-UMIN000010055Respiratory Center, Showa University Northern Yokohama Hospital20